Black Diamond Therapeutics

Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results

Establishing growing body of preclinical data evaluating the DNase-based oncology platform across a number of high-value oncology indications

Business Insider · 9d

Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Announced encouraging initial Phase 2 data of BDTX-1535 in patients with recurrent EGFRm NSCLC with a broad spectrum of classical, non-classical,

TMCnet · 1d

Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced its financial results for the third quarter ended September 30,

The Bakersfield Californian · 2d

Exodus Reports Third Quarter 2024 Results

Exodus Movement, Inc. (OTCQX: EXOD), (the “Company” or “Exodus”) the leading self-custodial cryptocurrency software platform, today announced its results for the third

Research Analysts Set Expectations for BDTX FY2024 Earnings

Equities research analysts at HC Wainwright upped their FY2024 earnings per share (EPS) estimates for shares of Black Diamond ...

19h

Acrivon Therapeutics, Inc.: Promising Advancements and Strong Buy Rating Backed by Innovative Pipeline and Solid Financial Position

TD Cowen analyst Marc Frahm has maintained their bullish stance on ACRV stock, giving a Buy rating today. Marc Frahm has given his Buy rating ...

Nasdaq13d

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Trending now